A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice

Cdk5 Protein Inhibition and Aβ42 Increase BACE1 Protein Level in Primary Neurons by a Post-transcriptional Mechanism

(2012) Katherine R. Sadleir et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

An experimental rat model of sporadic Alzheimer’s disease and rescue of cognitive impairment with a neurotrophic peptide

(2011) Silvia Bolognin et al.   ACTA NEUROPATHOLOGICA

Direct evidence of phosphorylated neuronal intermediate filament proteins in neurofibrillary tangles (NFTs): phosphoproteomics of Alzheimer's NFTs

(2011) Parvathi Rudrabhatla et al.   FASEB JOURNAL

Synaptic Deficits Are Rescued in the p25/Cdk5 Model of Neurodegeneration by the Reduction of  -Secretase (BACE1)

(2011) P. Giusti-Rodriguez et al.   JOURNAL OF NEUROSCIENCE

Cdk5 Is Required for Memory Function and Hippocampal Plasticity via the cAMP Signaling Pathway

(2011) Ji-Song Guan et al.   PLoS One

Cdk5: Multitasking between physiological and pathological conditions

(2011) Joao P. Lopes et al.   PROGRESS IN NEUROBIOLOGY

Silencing of CDK5 as potential therapy for Alzheimer’s disease

(2011) Alejandro López-Tobón et al.   REVIEWS IN THE NEUROSCIENCES

Antioxidant approaches for the treatment of Alzheimer’s disease

(2010) Hyun Pil Lee et al.   Expert Review of Neurotherapeutics

Quantitative phosphoproteomic analysis of neuronal intermediate filament proteins (NF-M/H) in Alzheimer's disease by iTRAQ

(2010) Parvathi Rudrabhatla et al.   FASEB JOURNAL

A 24-Residue Peptide (p5), Derived from p35, the Cdk5 Neuronal Activator, Specifically Inhibits Cdk5-p25 Hyperactivity and Tau Hyperphosphorylation

(2010) Ya-Li Zheng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Oxidative stress in Alzheimer disease: A possibility for prevention

(2010) David J. Bonda et al.   NEUROPHARMACOLOGY

Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases

(2009) Xiao-xia Dong et al.   ACTA PHARMACOLOGICA SINICA

Conditional Deletion of Neuronal Cyclin-Dependent Kinase 5 in Developing Forebrain Results in Microglial Activation and Neurodegeneration

(2009) Satoru Takahashi et al.   AMERICAN JOURNAL OF PATHOLOGY

Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer’s disease

(2009) Christopher J. Helal et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Cholesterol metabolism and transport in the pathogenesis of Alzheimer’s disease

(2009) Ian J. Martins et al.   JOURNAL OF NEUROCHEMISTRY

Transcriptional Regulation of β-Secretase by p25/cdk5 Leads to Enhanced Amyloidogenic Processing

(2008) Yi Wen et al.   NEURON